|Mr. David A. Cory R.Ph, MBA||Bus. Founder, Pres, CEO & Director||790.62k||N/A||1964|
|Dr. Jeffrey S. Glenn||Founder, Scientific Advisor & Director||44.75k||N/A||1963|
|Mr. James P. Shaffer MBA||Chief Bus. Officer||537.71k||N/A||1967|
|Dr. David Apelian||Director||752.07k||N/A||1965|
|Mr. Sriram Ryali M.B.A.||Chief Financial Officer||N/A||N/A||1981|
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Eiger BioPharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 9.